Market Place
Sourcing Support
BioLinerx Unveils 2025 Financials And Corporate Update
23 Mar 2026 //
PR NEWSWIRE
Biolinerx To Release Q3 2025 Results On Nov 24, 2025
18 Nov 2025 //
PR NEWSWIRE
Biolinerx Receives USPTO Notice For GLIX1 Cancer Treatment
17 Nov 2025 //
PR NEWSWIRE
BioLine Rx Reports Q2 2025 Financials, Updates on Corporate
14 Aug 2025 //
PR NEWSWIRE
BioLineRx to Announce Q2 2025 Results on August 14, 2025
08 Aug 2025 //
PR NEWSWIRE
BioLineRx to Report First Quarter 2025 Results on May 27, 2025
20 May 2025 //
PR NEWSWIRE
BioLineRx to Report 2024 Annual Results on March 31, 2025
24 Mar 2025 //
PR NEWSWIRE
BioLineRx Issues Letter to Shareholders
21 Jan 2025 //
PR NEWSWIRE
BioLineRx Alters ADS-To-Ordinary Shares Ratio
17 Jan 2025 //
PR NEWSWIRE
BioLineRx Announces $10 Million Registered Direct Offering
06 Jan 2025 //
PR NEWSWIRE
BioLineRx Reports Q3 2024 Financial Results, Updates
25 Nov 2024 //
PR NEWSWIRE
BioLineRx to Report Q3 2024 Results on November 25, 2024
20 Nov 2024 //
PR NEWSWIRE
BioLineRx Reports Q2 2024 Results And Recent Updates
15 Aug 2024 //
PR NEWSWIRE
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
08 Aug 2024 //
PR NEWSWIRE
BioLineRx: Q1 2024 Financials, Corporate & Portfolio Updates Reported
28 May 2024 //
PR NEWSWIRE
BioLineRx to Report First Quarter 2024 Results on May 28, 2024
22 May 2024 //
PR NEWSWIRE
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
17 May 2024 //
PR NEWSWIRE
BioLineRx presents economic model data for APHEXDA® at ISPOR 2024
06 May 2024 //
PR NEWSWIRE
BioLineRx Presents Apheresis Center Efficiency Data on APHEXDA®
17 Apr 2024 //
PR NEWSWIRE
BioLineRx Announces $6 Million Registered Direct Offering
01 Apr 2024 //
PR NEWSWIRE
BioLineRx Reports 2023 Financial Results
26 Mar 2024 //
PR NEWSWIRE
IM Cannabis to Report Fourth Quarter and Full Year 2023 Financial Results
20 Mar 2024 //
PR NEWSWIRE
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
20 Mar 2024 //
PR NEWSWIRE
BioLineRx Strengthens Intellectual Property Estate
04 Mar 2024 //
PR NEWSWIRE
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA
16 Feb 2024 //
PR NEWSWIRE
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
13 Nov 2023 //
PR NEWSWIRE
BioLineRx to Report Second Quarter 2023 Results on August 30, 2023
22 Aug 2023 //
PR NEWSWIRE
BioLineRx Announces Initiation of Phase 2 Trial in First Line Metastatic Pancreatic Cancer
17 Jul 2023 //
PR NEWSWIRE
BioLineRx Reports 1Q 2023 FYR and Recent Corporate and Portfolio Updates
24 May 2023 //
PR NEWSWIRE
BioLineRx to Report First Quarter 2023 Results on May 24, 2023
17 May 2023 //
PR NEWSWIRE
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
25 Apr 2023 //
PR NEWSWIRE
BioLineRx Announces Publication in Nature Medicine of its GENESIS Ph3 Trial
17 Apr 2023 //
PR NEWSWIRE
BioLineRx Reports Financial Results and Recent Corporate and Portfolio Updates
22 Mar 2023 //
PR NEWSWIRE
BioLineRx to Report 2022 Annual Financial Results on March 22, 2023
15 Mar 2023 //
PR NEWSWIRE
BioLineRx Announces Collaboration with Washington University School of Medicine
06 Mar 2023 //
PR NEWSWIRE
BioLineRx Announces Results from Ph1/2a Study of Invg Anti-Tumor Vaccine AGI-134
20 Dec 2022 //
PR NEWSWIRE
BioLineRx Reports Third Quarter 2022 Financial Results and Corporate Updates
15 Nov 2022 //
PRNEWSWIRE
BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA
10 Nov 2022 //
PRNEWSWIRE
BioLineRx to Report Third Quarter 2022 Results on November 15, 2022
10 Nov 2022 //
PRNEWSWIRE
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
04 Nov 2022 //
PRNEWSWIRE
BioLineRx to Present on Cost-Effectiveness of Motixafortide in Myeloma
03 Nov 2022 //
PRNEWSWIRE
BioLineRx Announces U.S. Commercialization Plan for APHEXDA
27 Sep 2022 //
PRNEWSWIRE
BioLineRx Announces $15 Million Registered Direct Offering
19 Sep 2022 //
YAHOO
BioLineRx Announces Submission of NDA to FDA for Motixafortide
12 Sep 2022 //
PRNEWSWIRE
BioLineRx Reports Second Quarter 2022 Financial Results
16 Aug 2022 //
PRNEWSWIRE
BioLineRx, GenFleet Enters Co-Development Agreement for Motixafortide in PDAC
29 Jun 2022 //
PRNEWSWIRE
BioLineRx Announces Collaboration Agreement with GenFleet Therapeutics in PDAC
28 Jun 2022 //
PRNEWSWIRE
BioLineRx Appoints Commercial Strategy and Operations Veteran H. W. May as CCO
16 Jun 2022 //
PRNEWSWIRE
BioLineRx Reports Q1 2022 Financial Results
11 May 2022 //
PRNEWSWIRE
BioLineRx to Report First Quarter 2022 Results on May 11, 2022
05 May 2022 //
PRNEWSWIRE
BioLineRx to Report 2021 Annual Results on March 16, 2022
10 Mar 2022 //
PRNEWSWIRE
BioLineRx Shows Results from Motixafortide + G-CSF to Plerixafor + G-CSF Study
03 Mar 2022 //
PRNEWSWIRE
BioLineRx Completes Enrollment of Phase 1/2a Study of AGI-134 in Solid Tumors
24 Jan 2022 //
PRNEWSWIRE
BioLineRx Announces Successful Completion of Pre-NDA Meeting for Motixafortide
18 Jan 2022 //
PRNEWSWIRE
BioLineRx Presents Data from Pivotal GENESIS Trial of Motixafortide plus
17 Dec 2021 //
TRIALSITENEWS
BioLineRx Reports Q3 2021 Financial Results and Provides Corporate Update
18 Nov 2021 //
PRNEWSWIRE
BioLineRx to Report Third Quarter 2021 Results on November 18, 2021
12 Nov 2021 //
PRNEWSWIRE
BioLineRx Announces an Oral Presentation & Three Poster Presentations at the ASH
04 Nov 2021 //
PRNEWSWIRE
BioLineRx Announces Positive Results from Pharmacoeconomic Study Motixafortide
13 Oct 2021 //
PRNEWSWIRE
BioLineRx shares rise 8% after Motixafortide study results
13 Oct 2021 //
SEEKINGALPHA
